What Is Melatonin and Why Are Dog Owners Using It?
Melatonin is a hormone naturally produced by the pineal gland in response to darkness, serving as the body's primary signal for the onset of sleep and the regulation of circadian rhythms. In humans, it is widely used as a sleep aid and mild anxiolytic, and that familiarity has driven its popularity as a supplement for dogs. Owners reach for it to manage noise phobias, separation anxiety, veterinary visit fear, and general stress. This often occurs without veterinary guidance, and often from products designed for human use, which may pose some health risks.
The appeal is understandable. Melatonin is widely available, inexpensive, and perceived as "natural" and therefore safe. The reality is more nuanced: there is genuine clinical evidence supporting its use in specific contexts, meaningful limitations on its evidence base, and several practical risks that make veterinary oversight more important than most owners realize.
How Melatonin Works in the Canine Brain and Body
Melatonin's calming effect in dogs is not simply a matter of inducing drowsiness. It operates through several distinct neurochemical and hormonal pathways that collectively reduce arousal and dampen the stress response.
GABAergic modulation: Melatonin acts as a mild agonist at GABA receptors, the primary inhibitory receptors in the central nervous system. By enhancing GABAergic signaling, melatonin increases the brain's inhibitory tone, reducing overall neuronal excitability and producing a state of calm without the degree of sedation associated with benzodiazepines. This mechanism is well-characterized and explains melatonin's documented preoperative calming properties in dogs. (Niggemann et al., 2019)
Dopamine modulation: Melatonin also modulates dopamine levels in specific brain regions. Since excessive dopaminergic activity can contribute to states of hyper-arousal, hyperactivity, and anxiety, this reduction in dopaminergic tone may help transition a dog from an aroused, reactive state toward a more relaxed behavioral baseline. (Niggemann et al., 2019)
HPA axis suppression and cortisol reduction: Physiologically, melatonin serves as an important regulator of the hypothalamic-pituitary-adrenal (HPA) axis, the body's primary stress response system. By interfering with key enzymatic steps in the adrenal cortex, melatonin can lower circulating cortisol. This was demonstrated directly in dogs: oral melatonin administered before and after ovariohysterectomy significantly decreased cortisol concentrations compared to untreated controls, while also increasing serotonin - a neurotransmitter important for mood stability. The anti-inflammatory effects were also documented, with significant reductions in acute-phase proteins (CRP, SAA) and the inflammatory cytokine IL-10. (Salavati et al., 2023)
Neuroinflammation and oxidative stress attenuation: Laboratory evidence suggests that the behavioral improvements seen with melatonin may be partly mediated by its ability to reduce neuroinflammation and oxidative stress within brain tissue. These mechanisms are increasingly understood as contributors to both anxiety and cognitive decline in aging animals. (Wang et al., 2021)
What the Clinical Evidence Shows
Veterinary hospital visits - the Chill Protocol
The most clinically relevant published evidence for melatonin's behavioral use in dogs comes from a 2023 prospective clinical trial published in JAVMA. Costa et al. enrolled 45 client-owned dogs between 1 and 12 years old, all with documented histories of anxiety, fearfulness, and/or aggression during veterinary visits. Dogs were assessed at a baseline visit and then received a pre-appointment protocol developed at Tufts University Cummings School of Veterinary Medicine (known as the "Chill Protocol" or GMA protocol) for their second visit.
The protocol consisted of oral gabapentin (20–25 mg/kg) the evening before the visit, followed by oral gabapentin (20–25 mg/kg), oral melatonin (3–5 mg/dog), and oral-transmucosal acepromazine (0.05 mg/kg) administered 90–120 minutes before the appointment. Examinations were videotaped and behavioral stress and sedation were evaluated using semiquantitative rating scales.
Pre-appointment administration of the GMA protocol significantly decreased stress scores and increased sedation scores in these anxious and fearful dogs compared to their untreated baseline visit. (Costa et al., 2023)
An important caveat: melatonin was not studied in isolation in this trial. It was administered alongside gabapentin (a known sedative and weak analgesic) and acepromazine (a tranquilizer). The specific contribution of melatonin to the overall reduction in stress scores cannot be isolated from this study design. This is an important limitation for owners and clinicians to understand: the evidence supports melatonin as part of a multimodal pre-visit protocol, not necessarily as a standalone anxiolytic.
Preoperative calming
Niggemann et al. (2019) evaluated melatonin's preoperative calming effect and its influence on propofol dose for anesthesia induction in healthy dogs. The study confirmed that melatonin produced a measurable calming effect prior to anesthesia and reduced the amount of propofol needed for induction, a clinically meaningful finding that suggests genuine CNS activity beyond placebo. (Niggemann et al., 2019). However, doses used in this study were significantly higher than other studies.
Compulsive disorder — case report evidence
Sacchettino et al. (2023) reported a case in which combining cannabis and melatonin treatment with a structured behavioral rehabilitation program improved symptoms in a dog with compulsive disorder, a condition characterized by constant, time-consuming repetitive behaviors that compromise daily activities. The authors described melatonin supplementation as useful for counteracting fear, anxiety, and phobia in dogs, and noted its ability to modulate mood-related behaviors and improve memory consolidation, consistent with its known neurochemical actions. (Sacchettino et al., 2023)
It is important to note this is a single case report, which is the lowest tier of clinical evidence. It supports the plausibility of melatonin's use in complex behavioral cases as part of a multimodal plan, but cannot be generalized.
Where Melatonin Has a Reasonable Evidence Base
Based on the current published literature, melatonin has the strongest support for the following specific applications in dogs:
- As part of a multimodal pre-visit protocol for dogs with documented veterinary visit anxiety, fearfulness, or aggression, when combined with gabapentin and acepromazine under veterinary direction
- As a preoperative calming agent to reduce procedural stress and potentially lower the required dose of induction agents
- As an adjunctive support in complex behavioral cases involving anxiety, compulsive behavior, or phobia, as part of a broader behavioral medicine and pharmacological plan
It has a weaker and less direct evidence base as a standalone daily supplement for generalized anxiety, noise phobia, or separation anxiety, though the mechanistic rationale is sound and some owners report benefit.
Clinical Limitations and Risks That Require Veterinary Oversight
Chronic use and endogenous suppression: Chronic administration of exogenous melatonin can lead to downregulation of the pineal gland's own melatonin production. Over time, this may disrupt the dog's natural circadian rhythm, potentially causing daytime lethargy, altered sleep-wake cycles, or disorientation, which is the opposite of the intended effect. Melatonin may be appropriate for situational use (pre-visit, pre-fireworks, perioperative) rather than indefinite daily supplementation without reassessment.
Product quality failures — the 400% label variation problem: The over-the-counter supplement market is poorly regulated, and melatonin is among the most inconsistently labeled products available. Studies in the human supplement market have documented actual melatonin content varying by over 400% from what is stated on the label; meaning a product claiming 3 mg may contain anywhere from less than 1 mg to over 9 mg. For a small dog, this range of actual doses has meaningfully different clinical implications. NASC-certified products — those that have undergone independent quality audits, provide greater assurance of label accuracy and product consistency.
Xylitol toxicity — a potentially fatal risk: Many human melatonin products, particularly gummies and chewables, contain xylitol as a sweetener. Xylitol is acutely toxic to dogs, causing dangerous drops in blood sugar (hypoglycemia) and potentially fatal liver failure, even at low doses. Owners who give dogs melatonin intended for human consumption, especially chewable or flavored formulations, face a serious and entirely preventable risk. Only products formulated specifically for veterinary use or verified xylitol-free human products should be considered, and then only under veterinary guidance.
Practical Guidance for Owners
If you are considering melatonin for your dog, the following principles apply:
- Consult your veterinarian first. Melatonin is most effective and safest when its use is guided by a clinical assessment of your dog's specific anxiety trigger, behavioral profile, and health status.
- Use only veterinary-formulated or verified xylitol-free products. Read every label. Do not assume any human supplement is safe.
- Consider NASC-certified products to reduce the risk of label inaccuracy and contamination.
- Reserve it for situational use rather than daily chronic administration unless your veterinarian has specifically recommended ongoing use with a monitoring plan.
- Do not use melatonin as a substitute for behavioral intervention. The strongest evidence for managing canine anxiety comes from multimodal approaches that combine pharmacological support with behavioral modification and environmental management. Melatonin is a useful adjunct, not a standalone solution.
Final Thoughts
Melatonin has a well-characterized mechanism of action in dogs, genuine physiological effects on the HPA axis and neurotransmitter systems, and meaningful clinical evidence supporting its use as part of multimodal pre-visit and perioperative protocols. The 2023 Costa et al. JAVMA trial and the Niggemann et al. 2019 anesthesia study represent the most methodologically sound evidence available, both confirming that melatonin contributes to reduced stress and calmer behavior in clinical settings.
What it does not have is strong evidence as a standalone daily supplement for chronic anxiety - the context in which most owners actually use it. The practical risks of product quality failure and xylitol exposure are real and serious. And the chronic use risks, while less acute, represent a meaningful reason to keep melatonin use under veterinary review rather than treating it as a permanently safe background supplement.
Used correctly, in the right clinical context, and from a verified-quality product, melatonin is a reasonable and evidence-supported tool in a canine behavioral medicine toolkit. The evidence simply does not support its casual, unsupervised long-term use.